CAP-IT Center for LNP RNA Immunoprevention
CAP-IT Center for LNP RNA Immunoprevention
批准号:
10505675
负责人:
NASSER Khaled ALTORKI
金额:
$118.06万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-01 至 2027-08-31
关键词:
AntigensArchitectureAutologousAwardBiotechnologyCOVID-19COVID-19 vaccineCancer BurdenCessation of lifeClinicClinicalClinical TrialsClonal EvolutionCommunicable DiseasesComputer AnalysisDataDatabasesDivision of Cancer PreventionEnsureGenomicsGoalsHealth Insurance Portability and Accountability ActHereditary Nonpolyposis Colorectal NeoplasmsImmuneImmunologic SurveillanceImmunopreventionIn VitroIndividualInfectionInheritedInterceptLesionLungLung AdenocarcinomaMalignant NeoplasmsMedicalNeisseria meningitidisNodulePatientsPoliomyelitisPredispositionPremalignant NeoplasmPreventionPrevention strategyPrimary Cancer PreventionRNARNA vaccinationRNA vaccineRecording of previous eventsRecurrenceResearchResource SharingRoleScienceServicesSmokerSumSyndromeT-LymphocyteTechnologyTranslatingTumor AntigensVaccinesValidationWorkbiobankcancer geneticscancer genomecancer genomicscancer immunotherapycancer predispositioncancer preventioncancer riskclinical translationcytotoxicity testefficacy testingexperienceflexibilityimmune RNAimmunogenicimmunogenicityin vivoin vivo Modelindividualized preventioninnovationlipid nanoparticlemouse modelneoantigenspatient populationpre-clinicalprogramssuccesstranscriptometumortumor immunologyvaccine discoveryvaccine formulation
中文摘要
总体组成部分:项目总结/摘要
CAP-IT RNA免疫预防中心(CRI)的总体目标是在临床前描绘、制定和
验证脂质纳米颗粒RNA(LNP RNA)疫苗,用于精确预防癌症增加的个体
风险PI是Lipkin博士,他是癌症预防领域的公认领导者,在临床上做出了几项重要的
翻译贡献给外地。项目1将开发和验证LNP RNA免疫预防疫苗
Lynch综合征,一种具有高度免疫原性复发性新抗原的遗传性癌症易感综合征
在不同病人的癌症中是相同的。项目2将开发和验证LNP RNA免疫
用于肺非实性结节(NSN)癌前病变患者的拦截疫苗,
腺癌前驱病变。为了实现这些目标,我们将使用最先进的技术,包括
LNP RNA疫苗制剂,计算基因组肿瘤免疫学,空间基因组学和
免疫肽组学为了确保CRI的科学严谨性和卓越性,我们已经组建了一个科学的
杰出的CRI外部顾问委员会(EAB),其中包括2021年拉斯克奖赢家德鲁·韦斯曼(Drew Weissman)
(Penn)在LNP RNA COVID 19疫苗方面的工作。总的来说,CAP-IT CRI将开发最先进的LNP RNA
免疫预防和免疫拦截疫苗,并提供技术上强大的平台,
启动其他CAP-IT CRI LNP RNA疫苗项目。我们预计,CAP-IT CRI将推动这两个
Lynch综合征和肺NSN疫苗在未来5年内进行NCI PREVENT和CP-NET临床试验
并在十年内获得FDA批准/临床翻译。
英文摘要
Overall Component: Project Summary/Abstract
The overall goal of CAP-IT Center for RNA Immunoprevention (CRI) is to pre-clinically delineate, formulate and
validate liponanoparticle RNA (LNP RNA) vaccines for precision prevention of individuals with increased cancer
risk. The PI is Dr. Lipkin, an established leader in Cancer Prevention who has made several important, clinically
translated contributions to the field. Project 1 will develop and validate an LNP RNA immunoprevention vaccine
for Lynch syndrome, a genetic cancer predisposition syndrome with highly immunogenic recurrent neoantigens
shared among cancers from different patients. Project 2 will develop and validate an LNP RNA immune
interception vaccine for patients with lung non-solid nodule (NSN) pre-malignant neoplasms, a lung
adenocarcinoma precursor lesion. To achieve these goals, we will use state-of-the-art technologies, including
LNP RNA vaccine formulation, computational genomic tumor immunology, spatial genomics and
immunopeptidomics. To ensure CRI's scientific rigor and excellence, we have assembled a scientifically
outstanding CRI External Advisory Board (EAB), which includes 2021 Lasker Award winner Drew Weissman
(Penn) for his work on LNP RNA COVID19 vaccines. Overall, the CAP-IT CRI will develop state-of-the-art LNP RNA
immunoprevention and immune interception vaccines and provide a technologically powerful platform to
jumpstart additional CAP-IT CRI LNP RNA vaccine projects. We anticipate that CAP-IT CRI will propel both
Lynch syndrome and lung NSN vaccines to NCI PREVENT and CP-NET clinical trials within the next 5 years
and FDA approval/clinical translation within ten years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunoregulatory role of lung-resident club cell factors in lung cancer
-
批准号:10587065
-
项目类别:
-
资助金额:$67.92万
-
财政年份:2023
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
Lung Cancer Vaccine
-
批准号:10505679
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2022
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
Intercepting progression from pre-invasive to invasive lung adenocarcinoma
-
批准号:10251562
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2020
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
Intercepting progression from pre-invasive to invasive lung adenocarcinoma
-
批准号:10024065
-
项目类别:
-
资助金额:$83.67万
-
财政年份:2019
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
Intercepting progression from pre-invasive to invasive lung adenocarcinoma
-
批准号:10465296
-
项目类别:
-
资助金额:$84.53万
-
财政年份:2019
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
Intercepting progression from pre-invasive to invasive lung adenocarcinoma
-
批准号:10666525
-
项目类别:
-
资助金额:$80.59万
-
财政年份:2019
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
Intercepting progression from pre-invasive to invasive lung adenocarcinoma
-
批准号:10117907
-
项目类别:
-
资助金额:$13.06万
-
财政年份:2019
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
Intercepting progression from pre-invasive to invasive lung adenocarcinoma
-
批准号:10738024
-
项目类别:
-
资助金额:$23.42万
-
财政年份:2019
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
Intercepting progression from pre-invasive to invasive lung adenocarcinoma
-
批准号:10532889
-
项目类别:
-
资助金额:$23.9万
-
财政年份:2019
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER
-
批准号:7604193
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2007
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
PH II STUDY/ PREOPERATIVE CELECOXIB/ PACLITAXEL/ CARBOPLATIN LUNG CANCER
-
批准号:7378376
-
项目类别:
-
资助金额:$1.38万
-
财政年份:2006
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
A PILOT STUDY OF NY-ESO PLUS CPG 7909 AND MONTANIDE IN PATIENTS WITH CANCER
-
批准号:7378392
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2006
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER
-
批准号:7378400
-
项目类别:
-
资助金额:$6.0万
-
财政年份:2006
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
A PHASE III RANDOMIZED, GROWTH FACTOR RECEPTOR ZD1839 (IRESSA)IN LUNG CA
-
批准号:7200393
-
项目类别:
-
资助金额:$0.29万
-
财政年份:2005
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
PH II STUDY/ PREOPERATIVE CELECOXIB/ PACLITAXEL/ CARBOPLATIN LUNG CANCER
-
批准号:7200370
-
项目类别:
-
资助金额:$1.53万
-
财政年份:2005
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
A PILOT STUDY OF NY-ESO PLUS CPG 7909 AND MONTANIDE IN PATIENTS WITH CANCER
-
批准号:7200389
-
项目类别:
-
资助金额:$0.87万
-
财政年份:2005
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER
-
批准号:7200401
-
项目类别:
-
资助金额:$3.72万
-
财政年份:2005
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
Ph. II study/ preoperative celecoxib/ paclitaxel/ carboplatin lung cancer
-
批准号:7040623
-
项目类别:
-
资助金额:$3.28万
-
财政年份:2004
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
A Phase II Randomized, Growth Factor Receptor ZD1839 (IRESSA)in Lung CA
-
批准号:7040647
-
项目类别:
-
资助金额:$0.24万
-
财政年份:2004
-
负责人:NASSER Khaled ALTORKI
-
依托单位:
海外基金